Faculty introduction, disclosures

Myelofibrosis overview Epidemiology Disease features and presentation Diagnosis Burden of disease Physical function effects Effects on mental wellbeing Survival

Treatment decision making in MF Factors influencing treatment decisions Risk stratification IPSS/DIPSS Low vs higher risk Symptoms Transfusion candidates Presence of thrombocytopenia Response to therapy Pharmacotherapeutic agents and targets Approved JAK inhibitors Emerging JAK inhibitors Novel approaches BCL inhibition XPO1/CRM1 inhibition Anti-CD123 BET inhibition MDM2 inhibition Clinical trial data Safety and efficacy Ongoing clinical trials: what’s next? Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe the burden of disease of MF.
• Assign a risk stratification category to a MF patient case to determine the optimal treatment approach.
• Recall the molecular drivers of disease in patients with MF.
• Contrast new and emerging treatment options, including efficacy, safety, and anticipated role in MF management.
• Develop a treatment plan for a MF patient using guideline-directed and evidence-based therapies.

ACCME Activity #202412824

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosure of Faculty: Eric Tam, MD, Assistant Professor of Clinical Medicine, Keck Medicine of USC, received financial compensation for speakers bureau from Medical Education Speakers Network.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from CTI BioPharma.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version